Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome: "The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of 40 mg per day of istradefylline (KW6002) in patients with Restless Legs Syndrome. "
Tuesday, May 23, 2006
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment